Autobacs Seven Co (AB6) fair value: what the stock is really worth
As of Oct 26, 2026: fair value (intrinsic value) of Autobacs Seven Co stock €7.70, price €8.67, upside -11.2%, quality 60 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value above price?No
Good quality?Yes
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 27, 2026.
How to read this chart
60‑month range €7.51 – €9.86 · fair‑value band €7.45 – €8.22 · the €8.67 price screens above the €7.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 27, 2026.
Follow Autobacs Seven Co in your weekly email
Every Wednesday you see whether Autobacs Seven Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Autobacs Seven Co., Ltd., together with its subsidiaries, operates a chain of retail stores for automotive goods and services in Japan and internationally. It operates through four segments: AUTOBACS Business; Consumer Business; Wholesale Business; and Expansion Business.
Show moreShow less
The AUTOBACS Business segment engages in the wholesale of car accessories, such as tires, wheels, and car electronics to franchisees.
The Consumer Business segment sells car accessories through physical stores, websites, and official apps, as well as offers installation, vehicle maintenance, and vehicle inspections services, and bodywork services; and purchases and sells vehicles.
The Wholesale Business segment engages in the wholesaling of lifestyle brands and other private brands, etc. The Expansion Business segment engages in credit-related businesses, insurance agencies, as well as provides financing, property and location development, and motorized bicycles.
The company was formerly known as Fuji-Syokai Co., Ltd. and changed its name to Autobacs Seven Co., Ltd. in March 1980. Autobacs Seven Co., Ltd. was founded in 1947 and is headquartered in Tokyo, Japan.
Stock analysis
Autobacs Seven Co (AB6) currently trades at €8.67, while our model-based Fair Value estimate is €7.70, 11.2% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €13.29 per share, and 8 of the 15 models we run sit above the €8.67 price.
Bear case: the Asset-Based group reads lowest at €1.32, and 7 of the 15 models stay below the price. Data coverage for this calculation is high.
Scenario range: €7.45 (bear) to €8.22 (bull), the price of €8.67 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Consumer Cyclical sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Autobacs Seven Co reported revenue of ¥280B in FY2026 versus ¥229B in FY2022, a compound +5.2%/yr. Reported net income was ¥8.4B in FY2026, compounding +4.5%/yr from FY2022.
Key figures
Market cap €681M Small · P/E ratio 14.7 · P/S ratio 0.44 · EPS (TTM) €0.5900 · Dividend yield 3.9% · Net margin 3.0% · Return on equity 5.9% · Return on assets (EBIT) 5.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (medium confidence).
What moves the price
The share trades about 7% below its 52-week high and 17% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Cyclical peers we cover trades at −24% fair-value upside, at −11%, AB6 screens cheaper than that median.
Fair Value models
Bear€7.45Fair Value €7.70Bull€8.22
Price €8.67 · Upside -11.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (€0.1434 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.37/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+12.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.9%
Start year 2021 (pandemic). Over 10 years: +3.0% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.6%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+7.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.8%
Dividend (yield on the price)3.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.3.8% vs 11.3%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 5%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Auto Parts · 663 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside−11.2% · Below median
Profitability
Return on equity (12 months)5.9% · Below median
Return on assets3.5% · Below median
Net margin (12 months)2.8% · Below median
Operating margin (12 months)3.4% · Below median
Growth and dividend
Revenue growth (quarter YoY)7.2% · Above median
Dividend yield (12 months)3.9% · Above median
Balance sheet
Debt / equity0.22× · Above median
Valuation Multiplesvs Auto Parts median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Autobacs Seven Co Fair Value". https://www.fairvalue-calculator.com/stock/AB6
Frequently asked questions
Is Autobacs Seven Co (AB6) overvalued or undervalued?
As of Oct 27, 2026, our model estimates a fair value of €7.70 versus a price of €8.67, about −11% upside (overvalued).
What is the fair value of AB6?
Our model-based fair value for Autobacs Seven Co is €7.70 (as of Oct 27, 2026), built from audited fundamentals. The current price: €8.67.
What is the quality score of AB6?
Autobacs Seven Co has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Autobacs Seven Co (AB6)?
Our model-based price target is the fair value of €7.70 (as of Oct 27, 2026) from 15 valuation models. Cautious scenario €7.45, optimistic scenario €8.22. It is a calculation from audited fundamentals, not an analyst target.
What is the Autobacs Seven Co stock forecast for 2026?
Our models put fair value at €7.70, about −11% upside versus a price of €8.67 (overvalued). Cautious scenario €7.45, optimistic scenario €8.22. The calculation is refreshed regularly with new filings.
What is the revenue of Autobacs Seven Co (AB6)?
Autobacs Seven Co reported trailing-twelve-month revenue of about ¥285B (latest available figure, as of Oct 27, 2026).
Does Autobacs Seven Co pay a dividend?
Autobacs Seven Co currently shows a dividend yield of 3.93% relative to its recent price (as of Oct 27, 2026).
What is the intrinsic value of Autobacs Seven Co (AB6)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Autobacs Seven Co it is €7.70 per share (as of Oct 27, 2026), against a price of €8.67. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Autobacs Seven Co stock overvalued or undervalued in 2026?
As of Oct 27, 2026, AB6 trades above its calculated fair value: price €8.67, fair value €7.70, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AB6?
No. The price is what the market pays today (€8.67); the fair value is what the company's own numbers justify (€7.70). For Autobacs Seven Co the two are €0.9665 per share apart. That gap is exactly why we show both numbers side by side.
How much is Autobacs Seven Co worth?
The market values Autobacs Seven Co at about €681M (market capitalisation, as of Oct 27, 2026). Per share that is €8.67; our models calculate a fair value of €7.70 per share.
What do the bullish and bearish scenarios say about AB6?
Our models span a range for Autobacs Seven Co: cautious scenario €7.45, base €7.70, optimistic €8.22 per share (as of Oct 27, 2026, price €8.67). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of AB6?
Autobacs Seven Co trades at a price-to-earnings ratio of 14.7 (as of Oct 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €7.70 is built from several models across several years. Other multiples: P/B 0.9, P/S 0.4, EV/EBITDA 6.1.
How solid is the balance sheet of Autobacs Seven Co (AB6)?
Balance-sheet figures for Autobacs Seven Co (as of Oct 27, 2026): return on equity 5.9%, debt of 0.22 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is AB6 from its 52-week high?
Autobacs Seven Co trades at €8.67, about 7% below its 52-week high of €9.33 and 17% above the low of €7.40 (as of Oct 23, 2026). Distance from the high says nothing about value: that is what the fair value of €7.70 is for.
Which stocks are comparable to Autobacs Seven Co?
From the same area (Consumer Cyclical) we also value O'Reilly Automotive, Inc, AutoZone, Inc, Hyundai Mobis Co, Fuyao Glass Industry Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Autobacs Seven Co stock attractive at the current price?
The data as of Oct 27, 2026: price €8.67, calculated fair value €7.70 (−11%), Quality Score 60/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AB6 calculated?
We run Autobacs Seven Co through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €7.70, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.7 % above its aggregate fair value. Autobacs Seven Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Autobacs Seven Co (AB6)?
The closing price on Oct 26, 2026 was €8.67. Our model-based fair value is €7.70, about −11% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Autobacs Seven Co right now?
The price sits above even our optimistic bull case (€8.22). The favourable scenario is already priced in. The models converge in a tight band (€7.45 to €8.22), unusually little disagreement for a valuation.
Key figures of Autobacs Seven Co
How large is the market capitalisation of Autobacs Seven Co (AB6)?
The market capitalisation of Autobacs Seven Co is €681M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Autobacs Seven Co (AB6)?
The price-to-sales ratio of Autobacs Seven Co is 0.44 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Autobacs Seven Co (AB6)?
Earnings per share at Autobacs Seven Co are €0.5900 (price ÷ EPS = P/E 14.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Autobacs Seven Co (AB6)?
The dividend yield of Autobacs Seven Co is 3.9% (payout 57.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Autobacs Seven Co (AB6)?
The net margin of Autobacs Seven Co is 3.0% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Autobacs Seven Co (AB6)?
The return on equity (ROE) of Autobacs Seven Co is 5.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Autobacs Seven Co (AB6)?
On an EBIT basis the return on assets of Autobacs Seven Co is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Autobacs Seven Co (AB6)?
The operating margin of Autobacs Seven Co is 3.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Autobacs Seven Co (AB6)?
Revenue at Autobacs Seven Co is growing +7.2% versus a year earlier (3y avg +5.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Autobacs Seven Co (AB6)?
Earnings per share at Autobacs Seven Co are growing −26.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Autobacs Seven Co (AB6) generate?
The free cash flow of Autobacs Seven Co is −¥2.4B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Autobacs Seven Co (AB6) carry?
The net debt of Autobacs Seven Co is ¥18.4B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Autobacs Seven Co in the live analysis
One click puts Autobacs Seven Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Broad data
Oct 27, 2026